Misclassification of drug failure in Plasmodium falciparum clinical trials in southeast Asia.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 19591576.
- Also identified by DOI 10.1086/600892 and PMC identifier 2761972.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most trials of antimalarials occur in areas in which reinfections are possible. For Plasmodium falciparum, reinfections are distinguished from recrudescences by polymerase chain reaction analysis of 3 polymorphic genes. However, the validity of this approach has never been rigorously tested. We tested for misclassification in 6 patients from clinical trials in Thailand and Cambodia who were classified as being reinfected by the standard polymerase chain reaction protocol. Using heteroduplex tracking assays and direct DNA sequencing, we found that 5 (83%) of 6 patients were misclassified. Misclassification in this manner overestimates the efficacy of antimalarials and delays the recognition of decreasing therapeutic efficacy, thus delaying potential changes in policy.
Medical subject headings
- Antimalarials
- Malaria, Falciparum
- Plasmodium falciparum